Genzyme drug test meets primary end point
Genzyme Corp., a Cambridge biotechnology company, said today that it is encouraged by test results for a potential treatment of heterozygous familial hypercholesterolemia, a disorder characterized by high cholesterol levels.
The treatment is called mipomersen, and Genzyme is working on mipomersen with Isis Pharmaceuticals Inc. of California.
In a press release, Genzyme and Isis said that a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia "met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo."
"With these data, we remain on-track with our development plan for mipomersen," Genzyme chief medical officer Richard A. Moscicki said in a statement.